The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
The Pandemic Agreement is here
In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...
Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Delinkage: New proposal offers a promising way forward on access, benefit sharing during pandemics
Members of the World Health Organization (WHO) last week picked up the task of navigating an unwieldy negotiation on a Pathogen Access and Benefit...
Time to put a stop to the abuse of orphan drug regulation- the latest...
Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...
On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...
Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...